Zevra Therapeutics Inc. Common Stock (ZVRA): valor razonable

Tesis ACCE

Zevra Therapeutics sells commercial rare-disease drugs, most notably Miplyffa (arimoclomol) for Niemann-Pick type C, alongside its Olpruva and Ojjaara-adjacent portfolio and a pipeline of orphan-indication programs. The structural appeal is the economics of orphan drugs: a 95.5% gross margin and a 42.3% operating margin on revenue growing 53.3%, with pricing power that comes from small, hard-to-serve patient populations and orphan exclusivity. Near-term, the story rests on Miplyffa's launch ramp and the conversion of a one-product growth profile into a multi-product one as additional indications and label expansions read out. At an 11.3x trailing and 10.7x forward earnings multiple, the market is pricing in little of that growth, and a 34.8% return on equity suggests the earnings are real rather than an accounting artefact of a single good quarter. The obvious question for a deeper look is durability: how much of the operating margin is sustainable once launch spending normalises and whether the pipeline can replace Miplyffa's revenue if competition or reimbursement pressure arrives.